|1.||Sigler, Eric J: 3 articles (02/2014 - 01/2013)|
|2.||Randolph, John C: 3 articles (02/2014 - 01/2013)|
|3.||Charles, Steve: 3 articles (02/2014 - 01/2013)|
|4.||Byon, Ik Soo: 2 articles (12/2015 - 09/2014)|
|5.||Lee, Ji Eun: 2 articles (12/2015 - 09/2014)|
|6.||Park, Keun Heung: 2 articles (12/2015 - 09/2014)|
|7.||Park, Sung Who: 2 articles (12/2015 - 09/2014)|
|8.||Olufsen, Marianne: 2 articles (11/2015 - 01/2014)|
|9.||Arukwe, Augustine: 2 articles (11/2015 - 01/2014)|
|10.||Calzada, Jorge I: 2 articles (04/2013 - 01/2013)|
|1.||Retinal Detachment (Retinal Detachments)
02/01/2014 - "Efficacy of short-term postoperative perfluoro-n-octane tamponade for pediatric complex retinal detachment."
04/01/1995 - "Experience with perfluoro-N-octane has demonstrated its usefulness both diagnostically and therapeutically as an intraoperative tool and improved the anatomic and visual outcome for retinal detachment complicated by severe PVR."
01/01/2015 - "Perfluoro-n-octane as a temporary intraocular tamponade in a staged approach to manage complex retinal detachments."
08/01/2014 - "But keeping perfluoro-n-octane for 3 days does not significantly reduce the risk of re-detachment with complex rhegmatogenous retinal detachment cases."
08/01/2014 - "Conclusion: Perfluoro-n-octane is efficacious and safe as a short-term vitreous substitute in primary rhegmatogenous retinal detachment repair cases with inferior/multiple breaks or GRTs or with extensive PVR. "
07/01/2013 - "Perfluoro-n-octane is efficacious and safe as a short-term vitreous substitute for repair of a recurrent RRD with advanced proliferative vitreoretinopathy requiring an inferior retinectomy."
01/01/2011 - "The aim of the study was to evaluate the ocular tolerance and efficacy of double filling with perfluoro-n-octane (n-C8F18) (PFO) and polydimethyloxane (PDMS) as a temporary vitreous substitute in patients with retinal detachment complicated by proliferative vitreoretinopathy (PVR). "
01/01/2015 - "To evaluate outcomes in patients with complex retinal detachments (RD) with proliferative vitreoretinopathy (PVR) requiring retinectomy using a staged approach utilizing perfluoro-n-octane (PFO) as a short-term postoperative intraocular tamponade. "
09/01/2003 - "Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study."
01/01/1994 - "The use of perfluoro-octane in the management of giant retinal tears without proliferative vitreoretinopathy."
|3.||Wounds and Injuries (Trauma)
07/01/2011 - "A case of a perfluoro-n-octane leakage into the orbital cavity after corneoscleral suture, scleral buckling and pars plana vitrectomy in an eye with perforating injury after trauma is reported for the first time. "
02/01/2014 - "Although cautions should be exercised regarding potential mechanical retinal injuries by heavy liquids in the eye, short-term perfluoro-n-octane tamponade was effective in pediatric cases with severe PVR in which retinal reattachment is considered to be difficult with conventional gas or silicone oil tamponade."
10/01/2002 - "Two hundred twelve patients (212 eyes) > or =15 months of age who underwent giant retinal tear management with intraoperative perfluoro-n-octane at 24 study sites between April 1994 and February 1996. "
12/01/2015 - "Perfluoro-n-octane Assisted Free Internal Limiting Membrane Flap Technique for Recurrent Macular Hole."
09/01/2014 - "Perfluoro-n-octane-assisted single-layered inverted internal limiting membrane flap technique for macular hole surgery."
07/01/2006 - "Using perfluoro-n-octane as a postoperative tamponade in the management of giant retinal tears."
10/01/2005 - "Perfluoro-n-octane as a postoperative vitreoretinal tamponade in the management of giant retinal tears."
01/01/2015 - "In this study, perfluorooctane emulsion (oxygen carrier)-loaded hollow microparticles (PFO-HPs) were prepared as a scaffolding system which can allow timely release of oxygen to cells adhered on the HPs to prevent cell necrosis in a hypoxic environment (inherently created in tissue engineered 3D constructs) until new blood vessels are formed in the 3D cell construct, and thus may produce appropriate tissues/organs with a clinically relevant volume. "
|4.||perfluorooctane sulfonic acid (perfluorooctane sulfonate)
|5.||Halogenated Diphenyl Ethers
|6.||Surface-Active Agents (Surfactants)
|7.||Sodium Chloride (Saline Solution)
|8.||Polychlorinated Biphenyls (PCBs)
|10.||Indocyanine Green (Cardio-Green)